| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Matthew R Plooster last filed a Form 4 in April 2023, as Director at ZVRA. Matthew R Plooster's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 18,500 shares of ZVRA. Net of sales, the ZVRA filings show accumulation of 16,000 shares.
Matthew R Plooster has 16 Form 4 filings on record from April 2015 to April 2023, all as Director at Zevra Therapeutics (ZVRA), 2015–2023.
The 23 reported transactions were 10 option or other derivative awards, 5 open-market purchases, 3 stock awards and 3 conversions, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 2 purchases worth about $71K and no sales.
The largest open-market purchase was 11,000 shares of ZVRA at an average $4.20 on March 9, 2023, about $46K. Twelve months later ZVRA was up 44%.
Shares as reported in the last Form 4 for each company; the most recent is from April 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.